Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · Real-Time Price · USD
206.27
-2.68 (-1.28%)
At close: Mar 5, 2026, 4:00 PM EST
206.20
-0.07 (-0.03%)
Pre-market: Mar 6, 2026, 8:16 AM EST
Ligand Pharmaceuticals Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Ligand Pharmaceuticals stock have an average target of 245.17, with a low estimate of 220 and a high estimate of 277. The average target predicts an increase of 18.86% from the current stock price of 206.27.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ligand Pharmaceuticals stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 4 | 4 | 4 |
| Buy | 4 | 3 | 3 | 3 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 6 | 7 | 7 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $275 → $277 | Buy | Maintains | $275 → $277 | +34.29% | Feb 27, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $231 → $239 | Strong Buy | Maintains | $231 → $239 | +15.87% | Feb 24, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $234 → $235 | Buy | Maintains | $234 → $235 | +13.93% | Dec 10, 2025 |
| Stifel | Stifel | Strong Buy Maintains $220 → $230 | Strong Buy | Maintains | $220 → $230 | +11.50% | Dec 10, 2025 |
| Citigroup | Citigroup | Strong Buy Initiates $270 | Strong Buy | Initiates | $270 | +30.90% | Dec 9, 2025 |
Financial Forecast
Revenue This Year
270.06M
from 268.09M
Increased by 0.74%
Revenue Next Year
321.47M
from 270.06M
Increased by 19.04%
EPS This Year
8.49
from 6.13
Increased by 38.52%
EPS Next Year
9.81
from 8.49
Increased by 15.56%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 291.9M | 360.5M | |||
| Avg | 270.1M | 321.5M | |||
| Low | 248.2M | 288.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 8.9% | 33.5% | |||
| Avg | 0.7% | 19.0% | |||
| Low | -7.4% | 6.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 9.19 | 10.70 | |||
| Avg | 8.49 | 9.81 | |||
| Low | 7.29 | 8.85 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 49.9% | 26.0% | |||
| Avg | 38.5% | 15.6% | |||
| Low | 18.9% | 4.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.